SCY-002P

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSCY-002P
Drug Alias NameCB-2 agonist and NMDA receptor/FAAH inhibitor (SOL Global Investments)CB-2 agonist and NMDA receptor/FAAH inhibitor (Scythian)SCY-002P
ClassificationSmall molecules
Mechanisms of ActionCannabinoid CB2 receptor agonistsGlutamate [NMDA] receptor antagonistsFatty-acid amide hydrolase 2 inhibitors
TargetsCannabinoid CB2 receptorFatty-acid amide hydrolase 2Glutamate [NMDA] receptor
Therapy Area/IndicationsEnteritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsYes
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesScythian Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesScythian Biosciences Inc
Active IndicationsN/A
Inactive IndicationsEnteritis

Other Information

ATC CodeN/A
Related LinksN/A